-+ 0.00%
-+ 0.00%
-+ 0.00%

Turn Therapeutics Q3 net loss more than triples to $6.23 million

PUBT·11/09/2026 12:03:21
Listen to the news
Turn Therapeutics Q3 net loss more than triples to $6.23 million
  • Turn Therapeutics' third-quarter 2026 net loss more than tripled year over year to $6.23 million.
  • Research and development spending more than tripled to $605,197, while general and administrative expenses fell 21% to $1.38 million.
  • Cash and equivalents totaled $10.36 million at September 30, with operations expected to remain funded into the third quarter of 2027.
  • Topline results from the ongoing Phase 2b atopic dermatitis trial of GX-03 are expected in the first quarter of 2027.
  • The planned Phase 2a hidradenitis suppurativa trial will begin enrollment in the first quarter of 2027, ahead of the second-quarter target.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109969887) on November 09, 2026, and is solely responsible for the information contained therein.